Working... Menu
Trial record 62 of 69 for:    Famotidine

Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01734759
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : October 21, 2013
Information provided by (Responsible Party):
Bernard Lee, Mayo Clinic

Brief Summary:
The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.

Condition or disease Intervention/treatment Phase
Healthy Drug: Taste Test Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers
Study Start Date : November 2012
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Taste Test Drug: Taste Test

Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.

Medications to be sampled and the corresponding dose of the test dose are:

  • Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg
  • Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg
  • Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg
  • Steroids: prednisolone 1.5 mg, prednisone 0.5 mg
  • H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg

Primary Outcome Measures :
  1. Taste scores on the visual analog scale [ Time Frame: Change from baseline in taste scores at 3 months ]
    Medication taste scores on the visual analog scale before and after a medication tasting will be measured.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • subjects possess prescriptive authority (e.g. MD, nurse practitioner, physician's assistant, medication therapy management pharmacists)
  • subjects have prescribed at least one of the study medications from one of the medication classes to pediatric patients at an outpatient clinic in the three months preceding the study

Exclusion Criteria:

  • subjects do not prescribe any of the tested medications
  • subject has an allergy to all of the study medications
  • subject is pregnant or breastfeeding
  • subject has a medical condition that prevents them from being involved in the taste test

Participants are advised to be within or accessible to the Rochester, MN area during study recruitment and accessible afterwards via mail, email or fax.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01734759

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Bernard Lee, PharmD, RPh Mayo Clinic
Principal Investigator: Ole J Olson, Pharm.D., BCPS Mayo Clinic
Study Director: Michelle J LoTurco, Pharm.D. Mayo Clinic

Layout table for additonal information
Responsible Party: Bernard Lee, Principle Investigator, Mayo Clinic Identifier: NCT01734759     History of Changes
Other Study ID Numbers: 12-005823
First Posted: November 28, 2012    Key Record Dates
Last Update Posted: October 21, 2013
Last Verified: October 2013

Keywords provided by Bernard Lee, Mayo Clinic:
medication palatability
medication taste